[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypoparathyroidism-post-surgical\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypoparathyroidism-post-surgical":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,81,111,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100630740","press--par-early-detection-and-prevention-of-symptomatic-postsurgical-hypoparathyroidism-after-thyroid-surgery-100630740",false,"NCT07491601","PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery\"","PRESSPAR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Thyroidectomy or bilateral thyroid resection of any indication\n* Written informed consent obtained after detailed patient information and provision of an information sheet\n\nExclusion Criteria:\n\n* Age ≤ 18 years\n* Concomitant parathyroid disease (primary or secondary hyperparathyroidism, pre-existing hypoparathyroidism of any cause)\n* Previous surgery in the neck region\n* Pregnancy or breastfeeding\n* Inability to attend study visits\n* Participation in another study that interferes with the endpoints\n* Missing or inadequate patient information","ALL","18 Years",{"count":19,"type":20},336,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to investigate whether an earlier measurement of parathyroid hormone can reduce the number of patients who develop symptomatic hypoparathyroidism. This will provide evidence for a clear algorithm to address this issue after thyroid surgery. It will lead to an improvement in quality of life and a reduction in the distress experienced by affected patients. In addition, it is conceivable that patients' hospital stay could be shortened.",[26,27,28],"Postoperative Hypoparathyroidism","Postsurgical Hypoparathyroidism","Hypoparathyroidism Post-surgical",[30,31,26,32,33,34,35],"Thyroid surgery","Perioperative medicine","Calcium supplementation","Active Vitamin D supplementation","Quality of life after surgery","Post-surgical Hypoparathyroidism","RECRUITING","2026-03-18",{"date":39,"type":40},"2026-03-24","ACTUAL",{"date":42,"type":40},"2025-01-08",{"date":44,"type":20},"2029-12-31",{"name":46,"class":47},"Nicolas Schlegel","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":48},"100589950","phase-1-parathyroid-allotransplant-for-treatment-of-hypoparathyroidism-100589950","NCT06961071","Parathyroid Allotransplant for Treatment of Hypoparathyroidism","Parathyroid Allotransplant for Treatment of Hypoparathyroidism: PATTH","PATTH","Inclusion Criteria Only subjects who meet all of the following criteria are eligible for enrollment.\n\n1. Subjects age 18 or older.\n2. Subjects who are able to provide written informed consent and to comply with study procedures.\n3. Clinical history and laboratory data compatible with HypoPT as defined by hypocalcemia and documented PTH levels either inappropriately normal or below the normal range on two occasions greater than 2 weeks apart and 12 months after surgery, requiring treatment with activated vitamin D (≥0.5 mcg calcitrol) and oral calcium (≥800mg) daily, or currently on PTH (1-84), PTH (1-34), palopegteriparatide or other recombinant parathyroid hormone replacement injections with ongoing symptomatology due to hypocalcemia and variable degree of biochemical control.\n4. No history of immunodeficiency (e.g., opportunistic infections) that could be exacerbated by immunosuppression.\n5. Up to date immunizations per the University of California, San Francisco (UCSF) standard of care for organ transplantation, including influenza, pneumococcal, hepatitis B, and tetanus-diptheria\n\nExclusion Criteria Subjects who meet any of the following criteria are not eligible for enrollment\n\n1. Presence of donor specific anti-HLA antibodies detected by Luminex Single Antigen\u002Fspecificity bead assay including weakly reactive antibodies that would not be detected by a flow cross match\n2. Intolerance to any drug that will be used as part of the IS regimen.\n3. Poorly controlled diabetes with an A1C of \\>8%.\n4. Blood Pressure (BP): systolic blood pressure (SBP) \\> 140mmHg or DBP \\>90 mmHg despite treatment with antihypertensive agents. If the BP is greater than 140\u002F90 chart review and discussion with the patient will be done to establish that BP is in good control.\n5. Other exclusion criteria including significant renal or hepatic dysfunction\n6. For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable.\n7. Active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB). Quantiferon gold assay will be used to determine TB infection.\n8. Invasive aspergillus, histoplasmosis, and coccidioidomycosis infection or other opportunistic infection within 1 year prior to study entry.\n9. Current malignancy or treated malignancy with estimated recurrence rate \\>50% at 5 years, except for completely resected squamous or basal cell carcinoma of the skin\n10. Known active alcohol or substance abuse.\n11. Active infections (except mild skin and nail fungal infections).\n12. Active peptic ulcer disease or gastritis, symptomatic gallstones, or portal hypertension.\n13. Use of any investigational agents within 4 weeks of screening or 5 half-lives of the investigational product\u002F medication, whichever is longer. Investigational products with prolonged invivo effects will require a wash-out period that aligns with the biochemical and physiologic effects of the agent prior to the initiation of this protocol. If the half life of the experimental agent is not known, participation in the study will be addressed with the study team and documented in the study record.\n14. Any investigational agents\u002Fproducts that could potentially interfere with the safety and\u002For efficacy of the procedure being studied will be addressed with the study team and documented in the study record.\n15. Administration of live attenuated vaccine(s) within 2 months of enrollment.\n16. Any medical condition that, in the opinion of the investigator, will interfere with safe study completion.\n17. Positive screen for polyoma (BK) viremia at time of screening.\n18. CKD stage 4 or 5\n19. Severe co-existing cardiac disease, characterized by any one of these conditions:\n\n    1. Recent myocardiol infarction (MI) (within 1 year)\n    2. Evidence of ischemia on functional cardiac exam within the last year. These include persantine thallium stress test and\u002For coronary angiogram which will be performed in any patient with a history of an MI\n    3. Left ventricular ejection fraction \\\u003C 45%\n    4. Valvular disease requiring replacement with prosthetic valve\n20. Substance use that in the opinion of the investigator would interfere with compliance with the study requirements.\n21. Past or current medical problems or findings from medical history, physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.",{"count":58,"type":20},3,[60,61],"PHASE1","PHASE2","This study is being done to see if transplanting parathyroid tissue into the forearm will help hypo-parathyroid patients achieve parathyroid hormone (PTH) levels that would help normalize their serum calcium and phosphorus levels. The parathyroid tissue used in this study will come from cadaveric tissues that were donated at the time of the death of the donor(s).",[64,65,28],"Hypoparathyroidism","Hypoparathyroidism Postprocedural",[67,68,69,70,71],"hypoparathyroidism","parathyroid hormone","PTH","serum calcium","phosphorus","2026-02-24",{"date":74,"type":40},"2026-02-27",{"date":76,"type":40},"2026-01-15",{"date":78,"type":20},"2028-01-15",{"name":80,"class":47},"Peter Stock",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":48},"100624939","comparing-pteye-assisted-versus-conventional-total-thyroidectomy-100624939","NCT07416149","Comparing PTeye-assisted Versus Conventional Total Thyroidectomy","Reducing Post-operative Hypoparathyroidism With Probe-based Near Infrared Autofluorescence (NIRAF)- Assisted Total Thyroidectomy Versus Conventional Total Thyroidectomy, a Randomized-controlled Trial","Inclusion Criteria:\n\n* Adult patients ≥18 years of age\n* Undergoing total thyroidectomy, or completion total thyroidectomy\n* Pre-operative serum adjusted calcium levels within normal ranges\n\nExclusion Criteria:\n\n* Patients on pre-operative calcium or vitamin D supplements\n* Patients with pre-operative vitamin D deficiency, defined as serum vitamin D\\\u003C30nmol\u002FL\n* Patients with untreated primary or secondary hyperparathyroidism\n* Patient with known non-surgical hypoparathyroidism diseases\n* Patients with estimated glomerular filtration rate \\\u003C30ml\u002F1.73m2\u002Fmin, on dialysis, or having a history of kidney transplant",{"count":89,"type":20},210,[23],"This is a prospective, single-blinded, randomized controlled trial to evaluate whether PTeye™ can reduce post-operative hypoparathyroidism (PH). The study will enroll consecutive patients undergoing total thyroidectomy in a teritary endocrine surgery unit in Hong Kong, randomizing them into receiving conventional surgery versus PTeye™-assisted surgery. Subjects will be assigned to the two groups before surgery. Subjects will be under medical care as in usual practice.",[93,94,28,95],"Hypocalcemia","Parathyroid","Total Thyroidectomy",[97,98,99,100,67,101],"Thyroidectomy","calcium","hypocalcemia","post operation","PTeye™ parathyroid detection system","2026-02-12",{"date":104,"type":40},"2026-02-17",{"date":106,"type":40},"2025-09-16",{"date":108,"type":20},"2028-12-31",{"name":110,"class":47},"The University of Hong Kong",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":48},"100574950","pteye-vs-surgeons-eyes-in-intraoperative-identification-and-functional-preservation-of-parathyroid-glands-during-thyroid-surgery-a-parallel-randomized-controlled-clinical-trial-100574950","NCT06765941","PTeye vs Surgeons Eyes in Intraoperative Identification and Functional Preservation of Parathyroid Glands During Thyroid Surgery: A Parallel Randomized Controlled Clinical Trial.","Clinical Validation of Probe-based Parathyroid Autofluorescence Detection System PTeye vs Surgeons Eyes in Intraoperative Identification and Functional Preservation of Parathyroid Glands During Thyroid Surgery: A Parallel Randomized Controlled Clinical Trial.","PTSURGEYE","Inclusion Criteria:\n\n* a patient with thyroid disease qualified for first-time total thyroidectomy.\n\nExclusion Criteria:\n\n* history of thyroid or parathyroid surgery,\n* planned simultaneous thyroid and parathyroid surgery,\n* renal failure,\n* pregnancy,\n* lactation,\n* allergy to contrast agents and\u002For iodine,\n* inability of the patient to understand the study protocol,\n* inability to participate in the planned postoperative follow-up,\n* age below 18 years.",{"count":120,"type":20},154,[23],"The goal of this randomized clinical trial is to learn if there are any added benefits of using near-infrared autofluorescence (NIRAF) probe-based imaging system (the PTeye) for intraoperative identification of parathyroid glands (PGs) during thyroid surgery in comparison to visual identification of PGs by the surgeon's naked eyes without PTeye.\n\nThe main questions it aims to answer are:\n\n* Is number of PGs identified intraoperatively and preserved in situ larger in thyroid operations with PTeye versus surgeon's naked eyes without PTeye?\n* Is number of patients with undetectable or low parathormone serum level on postoperative day 1 fewer in thyroid operations with PTeye versus surgeon's naked eyes without PTeye?\n* Is number of patients requiring substitution therapy with calcium and vitamin D analogue fewer after thyroid operations with PTeye versus surgeon's naked eyes without PTeye in a short-term (\\\u003C 6 weeks) and\u002For in a long-term (at 6 months) follow-up?\n* Is numer of inadvertenly removed and reimplanted PGs fewer in thyroid operations with PTeye versus surgeon's naked eyes without PTeye?\n* Is number of frozen sections fewer in thyroid operations with PTeye versus surgeon's naked eyes without PTeye?\n* Is number of PGs identified by pathologist in the surgical specimen fewer in in thyroid operations with PTeye versus surgeon's naked eyes without PTeye?\n* Is number of patients with symptomatic hypoparathyroidism within 30 days of the operation fewer in thyroid operations with PTeye versus surgeon's naked eyes without PTeye? The hypothesis explored in this study is that use of PTeye in comparison to the surgeon's naked eyes may be beneficial for intraoperative identification and preservation of PGs in thyroid surgery leading to reduced risk of postoperative hypoparathyroidism.\n\nA prospective, randomized study with 2 arms: use of PTeye vs. visual identification of PGs without PTeye (n=77 patients, each).\n\nThe primary outcome measure is number of intraoperatively identified PGs with use of PTeye vs without it.",[124,125,28],"Thyroid Surgery","Parathyroid Dysfunction",[127,128,129,130,131,132],"thyroid surgery","postoperative hypoparathyroidism","near-infrared autofluorescence","PTeye","probe-based parathyroid detection","visual identification","2025-08-25",{"date":135,"type":40},"2025-09-02",{"date":137,"type":40},"2025-08-23",{"date":139,"type":20},"2026-06-30",{"name":141,"class":47},"Marcin Barczynski",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":48},"100595609","phase-4-treatment-with-indapamide-in-patients-with-post-surgical-hypoparathyroidism-100595609","NCT07034677","Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism","HYPOCARE treat","Inclusion Criteria:\n\n1. Chronic post surgical hypoparathyroidism diagnosed \\> 1 year ago\n2. Age ≥ 18 years\n3. Require treatment with active vitamin D ≥ 1 µg\u002Fday\n4. Ionized plasma calcium between 1.15-1.25 mmol\u002FL\n5. 25(OH)D vitamin ≥ 50 nmol\u002FL\n6. Plasma magnesium \\> 0.65 mmol\u002FL\n7. Able to read and understand Danish\n8. Willing and able to sign the informed consent form\n\nExclusion Criteria:\n\n1. Estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73 m3\n2. Active cancer or former (except thyroid and basal cell skin) cancer treatment \\\u003C 1 year ago\n3. Pregnancy, pregnancy plans, or breastfeeding \\\u003C 1 year ago\n4. Abnormal arterial pressure at time of screening defined as symptomatic hypotension or systolic blood pressure \\\u003C 100 mmHg\n5. Plasma potassium \\\u003C 3.5 mmol\u002FL\n6. Any current disease that might affect the calcium metabolism such as but not limited to:\n\n   1. Recent prolonged immobility\n   2. Untreated diabetes (HbA1c \\> 53 mmol\u002Fmol)\n   3. Severe liver disease or hepatic encephalopathy\n   4. Untreated thyroid disease\n7. Current disease that might affect gastrointestinal absorption\n8. Use of medications such as lithium or diuretics within 4 weeks prior to start of treatment\n9. Known allergy or sensitivity to Indapamide, its excipients or sulfonamides\n10. Known galactosemia, lactase deficiency, or glucose-galactose malabsorption",{"count":150,"type":20},24,[152],"PHASE4","The aim of this study is to investigate the effect of daily treatment with Indapamide for 14 days on urinary calcium excretion in patients with post surgical hypoparathyroidisme.",[28],[67,156,157],"indapamide","hypercalciuria","2025-08-06",{"date":160,"type":40},"2025-08-11",{"date":162,"type":20},"2025-08",{"date":164,"type":20},"2025-12",{"name":166,"class":47},"Lars Rejnmark"]